Phase III randomized double blind placebo-controlled trial of FavId and GM-CSF versus placebo and GM-CSF following rituximab in subjects with follicular B-cell non-Hodgkin's lymphoma

Trial Profile

Phase III randomized double blind placebo-controlled trial of FavId and GM-CSF versus placebo and GM-CSF following rituximab in subjects with follicular B-cell non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Mitumprotimut T (Primary) ; Rituximab; Sargramostim
  • Indications B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 May 2009 Full results have been reported in the Journal of Clinical Oncology.
    • 09 Apr 2008 Data analysis and unblinding is expected in June 2008 according to a Favrille media release.
    • 19 Feb 2008 Favrille have reported that data collection is on schedule with the final analysis expected no later than July 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top